Biosion, Inc. and Celldex present positive preclinical data at SITC 2021. CDX-585 is the first compound from Celldex’s research and collaboration agreement with Biosion, Inc. and combines Celldex’s ILT4 mAb with Biosion’s PD-1 mAb.

Celldex Presents Positive Preclinical Data from PD-1/ILT4 Bispecific Antibody Program CDX-585 at SITC 2021

HAMPTON, N.J., November 12, 2021 — Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced positive preclinical data from CDX-585, the Company’s bispecific antibody with dual targeting of ILT4 and PD-1 checkpoint pathways, developed from its bispecific antibody platform. These data were presented in a poster session as part of the Society for Immunotherapy of Cancer’s 36th Annual Meeting (SITC 2021).

The data show CDX-585 effectively combines the blockade of ILT4 and PD-1 into one molecule, with favorable biophysical and functional characteristics, supporting the initiation of development activities including manufacturing and IND-enabling studies. CDX-585 is the first compound from Celldex’s research and collaboration agreement with Biosion, Inc. and combines Celldex’s ILT4 mAb with Biosion’s PD-1 mAb.

“We are pleased with this data which demonstrate we have successfully combined two important pathways into one molecule and support the further advancement of CDX-585,” said Tibor Keler, Ph.D., Executive Vice President and Chief Scientific Officer of Celldex Therapeutics. “We believe that co-targeting ILT4 and PD-1, which are both critical checkpoint pathways, has the potential to produce significant immune enhancing and antitumor effects. We are excited to move forward with CDX-585 in addition to the continued generation of other candidates from our bispecific antibody platform for oncology and inflammatory diseases.”

In the preclinical data presented at SITC, the simultaneous inhibition of ILT4 and PD-1 checkpoints with CDX-585 led to myeloid and T cell activation which may potentially demonstrate clinical utility, particularly in the T cell checkpoint inhibitor refractory setting. CDX-585 promoted T cell activation as measured by mixed lymphocyte reactions superior to that achieved by the combination of ILT4 and PD-1 monoclonal antibodies. CDX-585 also demonstrated anti-tumor activity in a humanized mouse model of melanoma and had a favorable pharmacokinetic profile in pilot studies, without adverse effects of treatment noted in clinical observations or clinical chemistry.

The poster presented at SITC can be viewed on the “Publications” page of the “Science” section of the Celldex website.

About CDX-585

CDX-585 is a dual targeting PD-1/ILT4 bispecific antibody from Celldex’s bispecific antibody platform, currently in preclinical studies including manufacturing and IND-enabling studies. Expression of ILT4 in several tumor types is associated with poor outcome and in preclinical models, antagonist antibodies to ILT4 have demonstrated immune enhancing and antitumor effects. CDX-585 is being developed as part of a research and collaboration agreement with Biosion, Inc.

About Celldex’s Bispecific Antibody Platform

Celldex’s deep antibody experience and in-house manufacturing capabilities support efficient development of next generation bispecific antibody programs for inflammatory/autoimmune diseases and oncology. Bispecific antibodies can engage two independent pathways involved in controlling immune reactions and combining these into one molecule can result in stronger activity than a combination of the independent antibodies. Targets are being selected based on new science as well as their compatibility to be used in bispecific antibody formats with Celldex’s existing antibody programs. Lead targets in development are emerging as important pathways controlling inflammatory diseases or immunity to tumors.

About Celldex Therapeutics, Inc.

Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer. Visit www.celldex.com.

About Biosion, Inc.

Biosion is a global clinical stage biotechnology company developing innovative therapeutics to address resistant, refractory, relapsed and residual disease for patients worldwide. The company is building its innovative pipeline through internally-derived proprietary technologies, including its H3 hybridoma platform, SynAb™ synergistic antibody evaluation, SynTracer™ HT-endocytosis screening and Flexibody™ bispecific platforms. Biosion is actively seeking global partners who are interested in licensing, partnership or co-development opportunities. For more information and full pipeline details, please visit www.biosion.com.

Forward Looking Statement

This release contains “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as “believes,” “expects,” “anticipates,” “intends,” “will,” “may,” “should,” or similar expressions. These forward-looking statements reflect management’s current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to successfully complete research and further development and commercialization of Company drug candidates, including CDX-0159, in current or future indications; the uncertainties inherent in clinical testing and accruing patients for clinical trials; our limited experience in bringing programs through Phase 3 clinical trials; our ability to manage and successfully complete multiple clinical trials and the research and development efforts for our multiple products at varying stages of development; the effects of the outbreak of COVID-19 on our business and results of operations; the availability, cost, delivery and quality of clinical materials produced by our own manufacturing facility or supplied by contract manufacturers, who may be our sole source of supply; the timing, cost and uncertainty of obtaining regulatory approvals; the failure of the market for the Company’s programs to continue to develop; our ability to protect the Company’s intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company’s products; our ability to continue to obtain capital to meet our long-term liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials that we have initiated or plan to initiate; and other factors listed under “Risk Factors” in our annual report on Form 10-K and quarterly reports on Form 10-Q.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.

Company Contact

Sarah Cavanaugh

Senior Vice President, Corporate Affairs & Administration

(508) 864-8337

scavanaugh@celldex.com

Patrick Till

Senior Director, Investor Relations & Corporate Communications

(484) 788-8560

ptill@celldex.com

Biosion, Inc. Raises ¥200M RMB Financing to Support Further Global Development of Its Innovative Pipeline

Newark, DE, Nanjing CN – Dec 10, 2020. Biosion Inc. (“Biosion”) today announced completion of ¥200 Million RMB (~$30 Million USD) of financing to transition Biosion into a clinical stage company within twelve months. The financing was led by Lapam Capital, joined by Kaiyuan Capital, Oceanpine Healthcare Fund, C&D Emerging Industry Equity Investment, and Zheshang Innovest.

“We are very grateful to the investors for their confidence and support in our innovative pipeline portfolio, our proprietary integrated technology platforms, as well as our senior management team. Funds from this round of financing will be used to support global clinical development of our innovative pipelines, and to strengthen our preclinical development capabilities of innovative discovery engine.” said Dr. Mingjiu Chen, Founder, Chairman and CEO of Biosion.

Mr. Zhihua Yu, the Chairman of Lapam Capital, said: “We are very optimistic for Biosion’s unique and differentiated innovation pipeline, their highly competitive technology platforms, and their development team with global pharmaceutical experience. We look forward to helping Biosion develop its innovative medicines to benefit patients world-wide.”

Biosion’s Chief Operating Officer and member of the Board of Directors, former Vice President of Janssen Pharmaceuticals, Dr. Hugh Davis said: “With our portfolio of over a dozen high-quality preclinical assets from our unique discovery platforms, we are confident that we will be able to quickly advance the global IND filing and clinical development, thus transforming Biosion into a clinical stage biotech company.”

About Biosion, Inc.

Biosion is a global R&D biotech company developing innovative therapeutics in the fields of immuno-oncology and immunologic diseases. The company is building its proprietary pipeline through internal R&D programs, co-development programs with partners and in-licensing efforts.

The Company integrates several internally-derived proprietary technologies,including its H3 hybridoma platform, SynAbTM synergistic antibody technology, SynKronTM bispecific platform, and SynTracerTM HT-endocytosis screening platform, to significantly accelerate its discovery efforts for novel molecules. The company has operations in Newark, Delaware and Nanjing, China. For more information and full pipeline details, please visit www.biosion.com

About Lapam Capital

Lapam Capital is a leading healthcare-focused venture capital firm in China and manages over 4 billion RMB funds. Lapam is the only biomedical professional investment institution that has received funding from the National Social Security Fund so far. Lapam Capital has invested in more than 50 innovative drugs and innovative medical device companies, including Betta Pharmaceuticals, RemeGen, Clover biopharmaceuticals, Binhui Biotech, Eyebright Medical Group, and many other industry elite companies. The number of domestic NDAs and new drugs approved in Lapam investment portfolio is among the best in the industry. Highly recognized in the industry, Lapam Capital is committed to providing their invested bio-pharmaceutical companies with comprehensive value-added services that may play a key role in the development of the company.

About Zhongguancun Kaiyuan Capital

Zhongguancun Kaiyuan Capital is an industry-finance linkage investment fund initiated by Zhongguancun Venture Capital, focusing on early-stage venture capital in the fields of information technology and biomedicine. Zhongguancun Venture Capital is a venture capital business platform under the Zhongguancun Management Committee and Zhongguancun Development Group. It mainly conducts venture capital through fund of funds investment and direct investment, and strives to promote the effective connection of technology and capital.

About Oceanpine Healthcare Fund

Oceanpine Healthcare Fund (“OHF”), a member of the Oceanpine Capital group, is a healthcare venture fund that aims to connect innovation in the US to the Chinese consumer base, and primarily invests in Chinese and US firms with core technologies and proprietary R&D capabilities. We bridge a supply and demand gap exacerbated by limited R&D in China. Our unique “Dual Market” strategy will help our portfolio companies with local resources and guidance, as well as providing diversification and value-realization for investors. We have established extensive partnership with academic institutions in the USA, such as University of Chicago, MD Anderson Cancer Center, etc., to bring the research projects from these institutions to China and achieve successful transformation of technology. Since our establishment, we have invested in multiple outstanding companies in both China and USA, including Human Longevity Inc. (Genome Technology), Edigene (Gene editing), Hua Dao Biotech (CAR-T), etc.

About C&D Emerging Industry Equity Investment

Established in 2014, C&D Emerging Industry Equity Investment is a corporate venture capital backed by Xiamen C&D Co. Ltd(234# of Fortune 500, 2020)and has become one of the most active players in direct equity investment and FoF market with over RMB 8 billion in capital under management. Our vision is to create value and support companies with high growth potential to achieve better development. We focus on investment in innovative and emerging industries such as healthcare, advanced manufacturing, and TMT/consumption.

About Zheshang Innovest

Zheshang Innovest manages the Zhejiang Zheshang Transform and Upgrade Fund of Funds Partnership(Limited Partnership). It is the vice chairman member of Zhejiang Equity Investment Industry Association and the vice chairman member of Zhejiang M&A Federation. The fund of funds was established under the guidance of the Zhejiang Provincial Finance Office with an approved scale of 10 billion RMB.

Media and Investor Contact:

Ailie Su

Biosion USA, Inc.

E-mail: IR@biosion.com

Biosion and ZhenGe Biotech Sign Global Strategic Partnership Agreement Accelerating Biosion’s Innovative Antibody Pipeline for IND Filing

NEWARK, Delaware, USA and NANJING, China, April 9,2020– Biosion Inc. and Shanghai ZhenGe Biotechnology Co. Ltd. jointly announced today that the two parties have signed a global strategic partnership agreement, to launch multiple projects with Biosion’s innovative antibody pipeline and ZhenGe’s CDMO (Contract Development and Manufacturing Organization) antibody technology platforms.

“We are very pleased to establish a strategic partnership with ZhenGeBiotech.” Said Dr. Mingjiu Chen, Founder, Chairman and CEO of Biosion Inc., “ZhenGe’s advanced one-stop CDMO services will facilitate CMC development of our innovative biologic pipeline and accelerate our timeline for IND filings and clinical development.”

“We look forward to working with like-minded partners,” said Mr. Jianxin Chen, Founder, Chairman and CEO of ZhenGe Biotech. “Biosion’s innovative pipeline and ZhenGe’s industry leading CMC platform complement each other perfectly. I believe our cooperation will greatly promote the development of the next generation therapeutical biologics for patients in need.”

According to this agreement, the two parties will leverage the competitive advantages of Biosion’s innovative antibody discovery pipeline and ZhenGe’s advanced CDMO technology platforms. This partnership is expected to accelerate Biosion’s innovative antibody therapeutic pipelines and at the same time take advantage of ZhenGe’s development capability and manufacturing capacity. ZhenGe will provide Biosion with strong support in process development and production efficiency to accelerate Biosion’s new biologic clinical trial applications (IND) in China and globally. Details of the partnership terms were not disclosed.

About Biosion, Inc.

Biosion, Inc. is a global biotechnology company, focusing on the discovery and development of innovative therapeutics for oncology and immunological diseases. Leveraging its proprietary H³ (High-throughput, High-content, High-efficiency) antibody platform and SynAb™ technology, the company is committed to discovering and developing innovative biologics for patients with unmet medical needs. Biosion has established a proprietary therapeutic pipeline through its internal discovery efforts and collaborations with other biotech and pharmaceutical companies. For more information, please visit www.biosion.com

About ZhenGe Biotech

Shanghai ZhenGe Biotechnology Co., Ltd., is a nationwide recognized high-tech enterprise registered in the Shanghai Free Trade Zone. ZhenGe specializes in biologics CDMO services. It has an advanced Trinity platform which integrates cell line development, process development and cell culture medium development in synergy. ZhenGe’s capabilities include customized cell culture medium development and production, cell line construction and genetic engineering, and a one-stop service system for biopharmaceutical CMC (Chemistry, Manufacturing, and Control). ZhenGe has recently closed its Series A financing, raising over $51M. Please visit www.zgbiotech.com for more information. 

Biosion, Inc. Appoints Hugh Davis, Ph.D., Chief Operating Officer and President of Biosion USA, Inc.

NEWARKDelaware, and NANJING, China. March 23, 2020 – Biosion Inc., announced the appointment of Hugh M. Davis, Ph.D., as Chief Operating Officer, Biosion, Inc. and President of Biosion USA, Inc.  Dr. Davis joins Biosion from Frontage Laboratories, Inc., where he served as Chief Business Officer.

“We are pleased to welcome Hugh to the executive team and Board of Directors of Biosion. Hugh brings a tremendous wealth of industry experience in biologics research & development and across the biopharmaceutical value chain, including both strategy and execution,” said Dr. Mingjiu Chen, Founder, Chairman and CEO of Biosion, Inc. “Based on our proprietary H³ antibody discovery platform and SynAb™ technology, Biosion has built an innovative biotherapeutics portfolio to address key unmet medical needs of patients with immune and oncology-related diseases. Hugh will be integral to developing and driving portfolio and corporate strategy for the next stage of our growth. He will also oversee our global business operations and clinical development of our innovative therapeutics portfolio.”

Dr. Davis is a seasoned executive with over 30 years of experience in the development of biologics therapeutics. At Janssen R &D/Johnson & Johnson, Hugh was Vice President & Head, Biologics Development Sciences, Biophysics and Laboratory Operations. He and his team were instrumental in the development and approval of many biologic therapies including Remicade®, Stelara®, Simponi®, Sylvant®, Tremfya® and Darzalex®.  Following his tenure at Janssen R&D, Hugh joined Frontage Laboratories, Inc. as Chief Business Officer, where he played a critical role in leading the company to a very successful IPO in May of 2019. Dr. Davis holds a Ph.D. in Biochemistry from Villanova University, Villanova, PA, USA.

About Biosion, Inc.

Biosion, Inc. is a global biotechnology company, discovering and developing innovative therapeutics for oncology and immunological diseases. Leveraging our proprietary H³ (High-throughput, High-content, High-efficiency) antibody platform and SynAb™ technology, the company is committed to discovering and developing innovative biologics for patients with unmet medical needs. The company is building a proprietary therapeutic pipeline through its innovative internal discovery efforts and through co-development programs in collaboration with biotech and pharmaceutical companies. For more information, visit www.biosion.com

Contacts:
Shengmei Ma
Biosion USA, Inc.
Newark, DE
+1-508-410-6008
shengmei.ma@biosion.com

Ailie Su
Biosion, Inc.
Nanjing, China
+86-199-5241-5530
ailie.su@biosion.com

Biosynergics, Inc. Completes Series A Financing and Company Restructuring

On October 29, 2017, Biosynergics, Inc. (“Biosynergics”), a China-based startup biotech company, announced that it has completed a 30 million RMB Series A financing. The Series A round was exclusively invested in by Shenzhen Renhe Capital. After completion of the financing, Shenzhen Renhe Capital (“SRC”) and Biosynergics co-registered a new entity named as Biosion, Inc. (“Biosion”) in Nanjing, China. Going forward, Biosynergics will operate as a wholly-owned subsidiary of Biosion.

The rationale for restructuring of Biosynergics was driven by three considerations. First, Biosyngerics has developed and directed its core antibody drug discovery business to minimize preclinical drug development risks while accelerating the clinical and commercial antibody drug pipeline success of its current and future biopharmaceutical clients. Second, Biosynergics has successfully recruited highly trained scientific talent to continue its execution on its business plan and will continue putting the effort of attracting more top talents in the near future. Third, the critical investment and restructuring required to create Biosion, now enables a strategic path forward to enhance and expand its capabilities as necessary through a future IPO. The newly established company, Biosion will focus on innovative antibody drug discovery and early preclinical drug development while Biosynergics will continue its existing business scope of In VitroDiagnosis(IVD) critical raw materials supply and CRO services.

Dr. Mingjiu Chen, Founder and CEO of Biosion stated “We are very pleased that our recent achievements and future growth potential were recognized by the Renhe Capital team. Exploiting our proprietary H³ (High-throughput High-content High-efficiency) antibody platform and SynAb™ (Synergistic Antibody) technology, we are able to interrogate very large, program-specific, antibody collections that result in the discovery and development of both First-in-Class and Best-in-Class antibody drug candidates. With SRC’s investment and their capital management experience, we anticipate that our antibody drug discovery pipeline will be accelerated and our corporate operation efficiency will be further optimized.”

“The demonstrated excellent performance of the Biosynergics team to date and the great growth potential of China’s biotechnology industry are the main considerations for today’s investment,” commented Mr. Weichun Ji, CEO of Shenzhen Renhe Capital. “Furthermore, leveraging their core business of innovative antibody drug discovery and early development, Biosion offers a very unique value proposition to its biopharmaceutical partners to increase the speed and success rate of their antibody drug development. Biosion team has demonstrated a combination of great technical expertise, a thoughtful and clear understanding of marketing strategy, and a strong implementation capability. During our due diligence, we have received very positive feedbacks from both Biosion’s current clients and from the experts from the industry. We are truly pleased to work with Biosion team to promote the innovation of China’s antibody drug industry.”

About Biosion, Inc.

Biosion is a China-based biotech company dedicated to the discovery and development of innovative antibody drugs. Based on our proprietary H³ antibody platform and SynAb™ technology, Biosion is committed to develop biological molecules with superior drug properties and/or novel mechanism of actions to known and novel drug targets. In the past years, Biosion team has successfully delivered multiple therapeutic antibody discovery projects to their clients, and established extensive business relations with the well-known biopharmaceutical companies in China. For more information, please visit www.biosion.com.

About Renhe Capital

Founded in 2012, Shenzhen Renhe Captial (SRC) is a professional asset management company. The company’s core management team investment experience has more than 19 years in the capital market with a wide range of network resources and customer resources, along with many fund management companies, securities companies, listed companies to maintain close relations of cooperation. On March 25, 2014, SRC was awarded the joint venture “private equity fund manager registration certificate” for the top 100 filing of the private management agencies by China Securities Investment Fund Association.

Close Bitnami banner
Bitnami